🔔 Rating Alert
Emkay Global Financial recommends buying Sun Pharma with a target price of Rs 2400.
Sun Pharma Analyst Rating
based on 37 analysts
71.05%
Buy
18.42%
Hold
10.53%
Sell
Based on 37 analysts offering long term price targets for Sun Pharma. An average target of ₹2053.68
Source: S&P Global Market Intelligence
Sun Pharma Share analysis
Sun Pharma price forecast by 37 analysts
Upside of15.49%
High
₹2450
Target
₹2053.68
Low
₹1610
Sun Pharma target price ₹2053.68, a slight upside of 15.49% compared to current price of ₹1762.7. According to 37 analysts rating.
Excluding Excise Duty and Other Income, represents Net Revenue
Sun Pharma revenue growth forecast
Expected growth rate Q1, FY2027:32.49%
Forecast
Actual
Including amortisation and stock based compensations
Sun Pharma EPS growth forecast
EPS estimate Q1, FY2027:56.05%
Forecast
Actual
Source: S&P Global Market Intelligence
Sun Pharma Performance
Day's Low
Day's High
₹1,759.5Day's Price Range₹1,805.7552 Week's Low
52 Week's High
₹1,29052-Week Price Range₹1,960.35
| Returns % | |
| 1 Month Return | -2 % |
| 3 Month Return | -6.26 % |
| 1 Year Return | + 29.02 % |
| Market Stats | |
| Previous Close | ₹1,778.25 |
| Open | ₹1,772.10 |
| Volume | 24.89L |
| Upper Circuit | - |
| Lower Circuit | - |
| Market Cap | ₹4,26,661.74Cr |
Sun Pharma Key Statistics
| P/E Ratio | 38.57 |
| PEG Ratio | 3.67 |
| Market Cap | ₹4,26,661.74 Cr |
| P/B Ratio | 16.41 |
| EPS | 40.21 |
| Dividend Yield | 0.83 |
| Sector | Pharmaceuticals |
| ROE | 12.05 |
Sun Pharma Peer Comparison
Company | Analyst View | Market Cap | 5 Year CAGR | Debt to Asset Ratio | Net Profit | Yearly Revenue |
|---|---|---|---|---|---|---|
| BUY | ₹4,26,661.74 Cr | 59.49% | 0.68 | ₹9,648 Cr | ₹48,496 Cr | |
| HOLD | ₹1,59,297.08 Cr | 44.15% | 0.50 | ₹1,600 Cr | ₹7,845 Cr | |
| BUY | ₹1,07,087.79 Cr | 42.65% | 0.67 | ₹1,656 Cr | ₹10,727 Cr | |
| BUY | ₹48,210.09 Cr | 7.26% | 0.58 | ₹1,297 Cr | ₹14,755 Cr | |
| HOLD | ₹27,623.92 Cr | -1.57% | 0.50 | ₹772 Cr | ₹5,664 Cr |
Sun Pharma Mutual Fund Holdings
About Sun Pharma
Sun Pharma's branded formulations include products for cardiovascular, central nervous system, gastroenterology, ophthalmology, and dermatology. Sun Pharma's specialty generics include injectables, inhalants, and complex products. Sun Pharma's API portfolio includes products for a range of therapeutic areas, including cardiovascular, central nervous system, gastroenterology, and dermatology.
Sun Pharma's top products include Modalert, a generic version of Modafinil for treating sleep disorders; Glocip, a generic version of Glipizide for treating diabetes; and Doxicip, a generic version of Doxycycline for treating bacterial infections. Sun Pharma's popular brands include Revital, a multivitamin supplement; Tazret, a topical retinoid for treating psoriasis; and Olmecip, a generic version of Olmesartan for treating hypertension.
Share Price: ₹1762.70 per share as on 21 Jan, 2025 04:01 PM
Market Capitalisation: ₹4,26,661.74Cr as of today
Revenue: ₹13,264.22Cr as on September 2024 (Q3 24)
Net Profit: ₹3,030.67Cr as on September 2024 (Q3 24)
Listing date: 08 Feb, 1995
| Organisation | Sun Pharma |
| Headquarters | Mumbai |
| Industry | Pharmaceuticals |
| E-voting on shares | Click here to vote |
Key events for Sun Pharmaceuticals Industries Ltd
Sun Pharma Receives Positive Outlook from Analysts - 21 Jan, 2025
Sun Pharmaceuticals is performing well in exports, especially in the US market. Emkay Global Financial has set a buy recommendation with a target of Rs 2400.Sun Pharma to Acquire Antibe Therapeutics Stake - 16 Jan, 2025
Sun Pharmaceutical Industries, through Taro Pharmaceuticals, has entered into an agreement to acquire 100% of Antibe Therapeutics, a clinical-stage biotech firm, enhancing its portfolio in pain management. The acquisition is subject to court approval and expected to complete by March 7, 2025.Analysts Recommend Buy for Sun Pharmaceuticals - 15 Jan, 2025
Analysts suggest buying Sun Pharmaceuticals at ₹1,770, with a target of ₹1,820-1,835, indicating potential upward movement based on technical analysis.Dilip Shanghvi's Family Acquires Mumbai Flats - 14 Jan, 2025
Dilip Shanghvi, chairman of Sun Pharma, and his family purchased two flats in Mumbai for Rs 130 crore. Shanghvi is a prominent figure in the pharmaceutical industry, leading Sun Pharma, India's largest pharmaceutical company with an annual revenue of $5.3 billion.JM Financial Maintains Buy Call on Sun Pharma - 13 Jan, 2025
JM Financial has reiterated a buy recommendation for Sun Pharmaceutical Industries with a target price of Rs 2,094. The company reported a consolidated total income of Rs 13,645.39 crore for the latest quarter, reflecting steady growth driven by market share gains and new product launches. Promoters hold a 54.48% stake, indicating strong confidence in the company's future.Sun Pharma Strengthens Specialty Portfolio and Growth Prospects - 11 Jan, 2025
Sun Pharmaceuticals is evolving into a specialty player with a robust portfolio and pipeline. The company is advised to accumulate shares on dips, despite high valuations. Key products like Ilumya show strong growth potential, and new partnerships and trials are set to enhance revenue streams. The strong balance sheet supports ongoing R&D and M&A opportunities, positioning Sun Pharma for sustained growth in both specialty and branded generics markets.Jefferies Recommends Sun Pharma for 2025 - 07 Jan, 2025
Jefferies has highlighted Sun Pharmaceutical Industries Ltd as a top pick among export-oriented companies for 2025, benefiting from strong market trends. The company is favored for its robust portfolio and potential for margin expansion.Sun Pharma Launches Sewing Training Centre in Jammu - 06 Jan, 2025
On January 6, 2025, Sun Pharma inaugurated a Sewing Training-Cum-Production Centre in Jammu, empowering 25 women from low-income communities as part of its CSR initiative.Sun Pharma's Long-Term Strategy Viewed Positively - 02 Jan, 2025
Sun Pharmaceuticals is recommended as a core holding for investors due to its strategic focus on developing a specialty portfolio, which is expected to yield significant long-term benefits despite potential short-term challenges.Sun Pharma Sells Japanese Subsidiary for Nominal Amount - 01 Jan, 2025
Sun Pharmaceutical Industries will sell its entire stake in Sun Pharma Japan Technical Operations to Zaza Industrial Holdings for JPY 1. The sale aligns with Sun Pharma's strategy to streamline operations, as the subsidiary contributed less than 0.5% to overall revenue. The transaction is expected to complete by January 31, 2025.Sun Pharma Shows Strong Bullish Momentum and Targets - 30 Dec, 2024
Sun Pharmaceuticals Industries Ltd is experiencing a bullish trend, with multiple analysts recommending buy positions and setting targets around Rs 1950. The stock has risen 49.14% over the past year, indicating strong performance in the market.Sun Pharmaceuticals Receives Buy Rating Upgrade - 28 Dec, 2024
Sun Pharmaceuticals has been upgraded to a 'Buy' rating due to strong financial performance, including a 10.05% growth in net sales and a 17.28% increase in operating profit. The company maintains a low debt-to-equity ratio and has shown consistent returns, generating a remarkable 48.73% return in the last year. With a market cap of Rs 4,41,838 crore, it holds a significant position in its sector.Analyst Recommends Bull Spread Strategy for Sun Pharma - 27 Dec, 2024
Nandish Shah from HDFC Sec suggests a Bull Spread strategy on Sun Pharma, highlighting a significant price breakout and bullish momentum indicators. Target price set at ₹1,920.Sun Pharma Reports Strong Growth and Share Performance - 24 Dec, 2024
Sun Pharmaceuticals Industries Ltd has demonstrated significant financial growth, with a 10.8% CAGR in revenue and a 24.6% increase in net profit over five years. The company's shares have appreciated by 45% in the past year, indicating strong market performance.
Insights on Sun Pharmaceuticals Industries Ltd
Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.
POSITIVE IMPACTFII Holding Up
Foreign Institutions have increased holdings from 17.23% to 18.02% in Sep 2024 quarter
- POSITIVE IMPACT
Revenue Rich
Revenue is up for the last 3 quarters, 12.58K Cr → 13.64K Cr (in ₹), with an average increase of 4.0% per quarter
- POSITIVE IMPACT
Profit Spike
Netprofit is up for the last 7 quarters, 1.98K Cr → 3.04K Cr (in ₹), with an average increase of 6.8% per quarter
- POSITIVE IMPACT
Best in 3 Years
In the last 3 years, SUNPHARMA has outperformed top 5 stocks with highest market-cap in Pharmaceuticals
NO EFFECTAgainst Peers
In the last 1 year, Divis Laboratories Ltd has given 46.6% return, outperforming this stock by 15.2%
- NO EFFECT
Promoter Holding Unchanged
Promoters holdings remained unchanged at 54.48% of holdings in Sep 2024 quarter
NEGATIVE IMPACTRetail Holding Down
Retail Investor have decreased holdings from 9.01% to 8.89% in Sep 2024 quarter
- NEGATIVE IMPACT
Price Dip
In the last 1 month, SUNPHARMA stock has moved down by -3.5%
- NEGATIVE IMPACT
MF Holding Down
Mutual Funds have decreased holdings from 12.78% to 12.11% in Sep 2024 quarter
News
Emkay Global Financial Recommends Buy on Sun Pharma with Target Price
Buy Sun Pharma; target of Rs 2400: Emkay Global Financial. Emkay Global Financials research report on Sun Pharma.21 Jan, 2025 11:55 AMIndian Drugmakers Expected to Benefit Under New US Government
Companies like Sun Pharma, Aurobindo, Dr Reddys, and Torrent Pharmaceuticals are doing exceedingly well on exports led by the key US market.21 Jan, 2025 12:53 AMSun Pharma Board Meeting for Q3 Results and Interim Dividend Announcement
Sun Pharmaceutical Industries Ltd is set to release its Q3 earnings for the quarter ending December 31, 2024, on Friday, January 31. The board will review and decide on the declaration of an interim dividend for the financial year 2024-25, as stated by the company in a filing with the exchange.17 Jan, 2025 02:14 PMSun Pharma Financials
Index Inclusions
Sun Pharma Shareholding Pattern
| Investors | Holdings % | FY Quarter | 3M change |
|---|---|---|---|
| Promoter Holdings | 54.48% | 0.00 | |
| Foreign Institutions | 18.02% | 4.60 | |
| Mutual Funds | 12.11% | ||
| Retail Investors | 8.89% | ||
| Others | 6.5% |
Sun Pharma Key Indicators
Sun Pharma Valuation
Sun Pharma in the last 5 years
Lowest (19.47x)
March 23, 2020
Today (38.57x)
January 20, 2025
Industry (55.28x)
January 20, 2025
Highest (184.63x)
August 28, 2020
Sun Pharma Earnings and Dividends
Sun Pharmaceuticals Industries Ltd Earnings Results
Sun Pharmaceuticals Industries Ltd’s net profit jumped 27.98% since last year same period to ₹3,040.16Cr in the Q2 2024-2025. On a quarterly growth basis, Sun Pharmaceuticals Industries Ltd has generated 7.21% jump in its net profits since last 3-months.
Read More about Earnings ResultsSun Pharmaceuticals Industries Ltd Dividends May,2024
In the quarter ending March 2024, Sun Pharmaceuticals Industries Ltd has declared dividend of ₹5 - translating a dividend yield of 0.99%.
Read More about Dividends
Sun Pharma Technicals Summary
Bearish
Neutral
Bullish
Sun Pharmaceuticals Industries Ltd is currently in a Bearish trading position according to technical analysis indicators.
FAQs on Sun Pharmaceuticals Industries Ltd
Sun Pharmaceuticals Industries Ltd share price today stands at ₹1762.7, Open. ₹1772.1 ; Previous Close. ₹1778.25 ; High. ₹1805.75 ; Low. ₹1759.5 ; 52 Week High. ₹1960.35 ; 52 Week Low: ₹1290.
- Get a PAN card.
- Open a Demat account.
- Open a Trading account.
- Link your Demat account to your Trading account.
- Fund your Trading account.
- Place an order to buy Sun Pharmaceuticals Industries Ltd shares.
Sun Pharmaceuticals Industries Ltd is listed on NSE
Sun Pharmaceuticals Industries Ltd is listed on BSE
- Today’s highest price of Sun Pharmaceuticals Industries Ltd is ₹1805.75.
- Today’s lowest price of Sun Pharmaceuticals Industries Ltd is ₹1759.5.
PE Ratio of Sun Pharmaceuticals Industries Ltd is 38.57
PE ratio = Sun Pharmaceuticals Industries Ltd Market price per share / Sun Pharmaceuticals Industries Ltd Earnings per share
Today’s traded volume of Sun Pharmaceuticals Industries Ltd(SUNPHARMA) is 24.89L.
Today’s market capitalisation of Sun Pharmaceuticals Industries Ltd(SUNPHARMA) is ₹426661.74Cr.
| Sun Pharmaceuticals Industries Ltd(SUNPHARMA | Price |
|---|---|
52 Week High | ₹1960.35 |
52 Week Low | ₹1290 |
Sun Pharmaceuticals Industries Ltd(SUNPHARMA) share price is ₹1762.7. It is down -10.08% from its 52 Week High price of ₹1960.35
Sun Pharmaceuticals Industries Ltd(SUNPHARMA) share price is ₹1762.7. It is up 36.64% from its 52 Week Low price of ₹1290
| Sun Pharmaceuticals Industries Ltd(SUNPHARMA | Returns |
|---|---|
1 Day Returns | -15.55% |
1 Month Returns | -2% |
3 Month Returns | -6.26% |
1 Year Returns | 29.02% |